Clinical Trial Update: ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of ONO-4538 (nivolumab) in patients with advanced non-small cell lung cancer has completed. Results were posted on 2024-12-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2024-12-09